Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood tests could simplify Wilson's disease monitoring

NCT ID NCT07462026

Knowledge-focused Sponsor: Hacettepe University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at two new blood tests, called exchangeable copper (EC) and relative exchangeable copper (REC), to see if they could better monitor Wilson's disease than standard tests. Researchers compared these blood tests with usual copper measurements in 81 adult patients with Wilson's disease and a control group. The goal was to see if EC and REC could provide a simpler and more accurate way to track the disease during follow-up.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, these blood tests could offer a simpler, more accurate way to monitor Wilson's disease, potentially replacing 24-hour urine collections.
What could go wrong
This is a small, completed observational study, not a treatment trial. The tests may not prove more useful than existing methods in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

81 people

The number who actually took part.

Started

Jan 2021

Finished

Sep 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of adult patients with Wilson's disease who were followed at the gastroenterology and neurology outpatient clinics of a tertiary university hospital. A control population was selected from adult patients presenting with dyspepsia at the same institution. Control participants were matched to patients with Wilson's disease by age and sex. All participants were recruited from the same hospital setting during the study period.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Wilson's Disease Group: * Adult patients (≥18 years) diagnosed with Wilson's disease * Followed at gastroenterology and/or neurology clinics * Clinically stable at the time of study inclusion * Provided written informed consent Control Group: * Adult patients (≥18 years) with dyspepsia * No known diagnosis of Wilson's disease or other disorders of copper metabolism * Age- and sex-matched to patients with Wilson's disease * Provided written informed consent Exclusion Criteria: (Applied to both groups unless otherwise specified) * Acute liver-related disease or complications, including: * Acute liver failure * Acute-on-chronic liver failure * Spontaneous bacterial peritonitis * Hepatic encephalopathy * Hepatorenal syndrome * Presence of diseases affecting copper metabolism other than Wilson's disease, including: Menkes disease, Malnutrition, Malabsorption syndromes * Inability or unwillingness to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Wilson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Wilson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Wilson's disease

Contacts and locations

Locations

  • Hacettepe Üniversitesi İç Hastalıkları Anabilim Dalı

    Ankara, Sıhhıye, 06100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.